Oncology biotech is having a moment again, and Genmab is at the center of it after three Phase 3 wins and a share price that has doubled in just three months. When one developer suddenly has multiple cancer drug contenders, attention often spills over into other treatment players that might benefit from the same wave of interest or face tougher competition. This article unpacks what that shift could mean by walking through three oncology stocks that are directly exposed to the latest Genmab news and why their stories may deserve a closer look right now, whether you are hunting for opportunity or trying to avoid a potential value trap.
The three oncology stocks below are only a small sample of what this Genmab driven ripple effect touches, and the broader screen pulled out 25 more listed cancer specialists with equally detailed stories that are not broken down here.
If you want to move beyond anecdotes and quickly identify, compare, and analyze those additional oncology ideas, head straight to the Oncology-focused biotechnology stocks screener.
CG Oncology (CGON)
CG Oncology fits neatly into this oncology-focused screener because it is a pure play on cancer drug development, with a single oncolytic bladder cancer therapy moving through late-stage trials that could reshape how a specific group of patients are treated if the data and approvals ultimately follow.
CG Oncology generates its US$6 million in revenue from biotechnology activities, all in the United States, and has a market value of about US$5.7b that reflects investor focus on its late stage cancer program and potential commercial path in bladder cancer rather than current sales.
For investors tracking how late stage oncology platforms might turn focused science into scale, CG Oncology slots directly into the current Genmab driven spotlight on immuno oncology, without overlapping its specific tumor types, and offers a more concentrated bet on bladder cancer therapy development that is already moving toward commercial planning.
"Planned expansion of cretostimogene into intermediate risk and BCG exposed NMIBC, supported by the fully enrolled 364 patient PIVOT-006 trial and the planned randomized Phase 3 in roughly 50,000 BCG exposed patients, could materially widen CG Oncology’s treated population and influence future revenue scale."
What ultimately happens to CG Oncology’s future earnings power hinges on how one less visible constraint shapes the economics behind that potential reach.
That hidden constraint is exactly what the full narrative for CG Oncology unpacks, revealing how trial design, pricing power, and capital runway could accelerate or cap CG Oncology’s eventual upside.
BeOne Medicines (ONC)
BeOne Medicines sits right in the middle of this oncology-focused screener, with a global footprint in cancer drugs that already reach patients across blood and solid tumors, and a pipeline built to matter more if late stage data keep lining up.
"The chemo free BRUKINSA plus rituximab regimen in the Phase 3 MANGROVE study, which reduced progression or death risk by 43% versus bendamustine plus rituximab and is heading toward filings in the second half of 2026, can reposition BeOne Medicines more toward continuous, higher value frontline B cell malignancy care that supports longer duration revenue per patient."
What happens to BeOne Medicines’ future earnings profile depends heavily on how one quiet trade off between pricing discipline and rising fixed costs plays out.
BeOne Medicines is a pure play oncology group that discovers, develops, and sells cancer medicines worldwide, generating about US$6.1b from pharmaceutical products and carrying a market value near US$42.1b.
That trade off is where things get interesting, and the full narrative for BeOne Medicines maps how pricing, fixed costs, and pipeline optionality could be quietly accelerating BeOne Medicines’ risk reward profile.
Zymeworks (ZYME)
Zymeworks is one of the clearest fits for this oncology-focused biotech screen, using antibody platforms and antibody-drug conjugates to build a portfolio of cancer therapies while earning US$37 million from developing next generation multifunctional biotherapeutics and carrying a market value of about US$2 billion.
Investors hunting for pure oncology platform exposure will find Zymeworks in the middle of this theme, with its bispecific antibodies, ADCs, and T cell engagers giving it multiple shots on goal as partners push programs deeper into solid tumors and blood cancers.
"Expansion of Ziihera into additional tumor types and earlier treatment settings through the planned global development program could support higher royalty revenue and improve earnings as incremental sales build on the existing first line HER2 positive GEA position."
The real swing factor is how one quiet choice about funding future deals shapes the balance between growing royalties and pressure on margins.
That funding choice is where the full narrative for Zymeworks pulls everything together, showing how Zymeworks’ deal structure, royalties, and cash needs could be quietly decoupling risk from upside.
Seeking Alternatives Before Everyone Else?
Fresh ideas move first. Breakout themes, rising momentum, and under the radar stocks often get caught once the crowd piles in. Scan these picks while it matters and act now.
- Spot income workhorses early and review the 4 dividend fortresses before yields compress and stronger cash returns become harder to find.
- Track the next infrastructure backbone and assess the 43 power grid technology and infrastructure stocks while grid technology upgrades are still flying under most radars.
- Secure your watchlist of future disruptors and filter the 19 high quality undiscovered gems before fresh institutional money starts chasing the same limited set of ideas.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com